A XENOTHERAPY PLATFORM WITH EMBEDDED TECHNOLOGY
THAT RENOVATES IMMUNOLOGICAL TREATMENTS

Innovative immunotherapy

XENOTHERA’s platform for creating of hyperimmune polyclonal sera is based on the following proprietary processes:

Define the proper animal and its genetic background for engineering
Choose and optimize the immunogen
Turn the animal’s immune response for an optimized therapeutic efficiency
Purify the antibodies
Lead a translational development program
Product and commercialize

Therapeutic domains:

Immunology
Infectious diseases
Anti-toxins and venoms
Oncology
Others

TEAM

Odile Duvaux

Chief Executive Officer

M.D., Ph. D., formerly main partner in a consultant firm specialized in strategy DMJ Consultants

More

Bernard Vanhove

Chief Operating Officer

Ph. D., immunilogist, formerly Research Director at CNRS and INSERM, co-founder and ex-COO of Effimune

More

Didier Coquoz

Clinical & Regulatory Affairs

PhD in clinical pharmacology, Chief Development and Regulatory Officer for biotech/small pharmas

More

Alexandre Lemoalle

Business Development

Former M&A VP for Sanofi, had many finance experiences in the pharmaceutical industry

More

Elsa Lheriteau

Project Manager

Ph. D. in Gene Therapy, Molecular Biology and Vectorology, University of Nantes, France

More

Pierre-Joseph Royer

Research Engineer

Ph. D. in Immunology, University of Nantes, France

More

Carine Ciron

Research Engineer

Ph. D. in Gene Therapy, Molecular Biology and Vectorology, University of Nantes, France

More

Gwenaelle Evanno

Research

Masters in Biochemistry, University of Rennes, France

More

Juliette Rousse

Research

Masters from University of Nantes, France, completing her Ph. D. with Xenothera

More

Sophie Despons

Administration & Finance

External Contractor
Scientific advisor

Jean-Paul Soulillou

Emeritus Professor of Medicine, worldwide renowned immunologist. 2016 winner of the Medawar Prize

More
External Contractor
Scientific advisor

Emanuele Cozzi

Chairman of the Scientific Advisory Board

MD, Professor of Immunology at the University of Padua, former chairman of the International Xenotransplantation Association

More
External Contractor
Scientific advisor

Jean-Marie Bach

D.M.V., Ph.D., Professor at Oniris, Veterinary school of Nantes

More
External Contractor
Scientific advisor

Sophie Brouard

D.M.V., Ph.D., leads a team of 32 researchers at ITUN, specialist in immunology and transplantation

More
External Contractor
Genetic Engineering

Cesare Galli

D.M.V., Ph.D., founder of the company Avantea (Cremona, Italy), worldwide renowned animal genetic engineer

More
External Contractor
Development & Market Access

Marc Bouillet

M.D., former partner/CEO in several pharmaceutical companies and patient associations

More

An agile company with a fast-paced development

XENOTHERA is a biotechnology start-up company at the top of innovation, which creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases. Our technological platform is built on a double expertise of animal genetics and mastery of immunological processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Our antibodies are engineered to display specific properties with reduced adverse effects and enhanced biological properties. XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale.

Pipeline

Products in development

Latest News

Xenothera receives approval for first in man Kidney Transplant Clinical Trial

Nantes, September 11th, 2019 – Xenothera announces it has received  Czech Republic regulatory agency approval to begin its Phase I/II clinical trial of its LIS1 product developed as induction treatment in solid organ[…]

Read more

Xenothera presents at ESOT 2019

XENOTHERA will participate at ESOT 2019 that will take place in Copenhagen in Sept.19.During the congress the preclinical data obtained with the first product, LIS1, for prevention of graft rejection,[…]

Read more

Xenothera announces receivability of its Clinical Trial Application at the Czech Republic regulatory agency for a first in man clinical trial of LIS1 in kidney transplanted patients with dose escalation.

Nantes, June 21st, 2019 – Xenothera announces receivability after its submission of a Clinical Trial Application (CTA) with Czech Republic regulatory agency for a Phase I/II trial of its LIS1 product developed as induction[…]

Read more

Xenothera is built on a worldwide network of scientific partners

Related scientific papers

Anti-Gal and anti-Neu5GC responses in non-immunosuppressed patients following treatment with anti-thymocyte globulin

Salama et al, ESOT 2017, Oral presentation Transplant International, volume 30, Supplement 2

LINK

Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs.

Salama et al, Diabetes, 2017

LINK

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs

Reynard et al, PLoS One. 2016

LINK

Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival

Couvrat-Desvergnes et al, J Clin Invest. 2015

LINK

Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation.

Salama et al, Xenotransplantation. 2015

LINK

Long-term IgG response to porcine Neu5Gc-antigens without transmission of PERV in burn patients treated with porcine skin xenografts

Scobie et al, J Immunol. 2013

LINK

To contact us, use the form or see our full contact below

Xenothera
1 rue Vauban – 44000 Nantes – France

Xenothera is a start-up in biotechnology, specialized in immunology, infectious diseases and oncology

Investors already trusted us in 2014, 2016 and 2018 by funding the company for 6M€. We are raising an additional 10M€ in 2019 to complete the first-in-man clinical trial of our first product. Our products will offer a substantial patient benefit and address unsolved major public health issues


[recaptcha]